NEW YORK – Allarity Therapeutics said on Friday that due to pandemic-related manufacturing delays, it is now expecting to file the new drug application for its investigational kidney cancer drug dovitinib with US regulators next year.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.